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Disrupted glycosylation of lipids and proteins is
a cause of neurodegeneration
Tobias Moll, Pamela J. Shaw and Johnathan Cooper-Knock
Glycosyltransferases represent a large family of enzymes that catalyse the biosynthesis of oligosaccharides, polysaccharides, and
glycoconjugates. A number of studies have implicated glycosyltransferases in the pathogenesis of neurodegenerative diseases but
differentiating cause from effect has been difficult. We have recently discovered that mutations proximal to the substrate binding
site of glycosyltransferase 8 domain containing 1 (GLT8D1) are associated with familial amyotrophic lateral sclerosis (ALS). We
demonstrated that ALS-associated mutations reduce activity of the enzyme suggesting a loss-of-function mechanism that is an
attractive therapeutic target. Our work is the first evidence that isolated dysfunction of a glycosyltransferase is sufficient to cause a
neurodegenerative disease, but connection between neurodegeneration and genetic variation within glycosyltransferases is not new.
Previous studies have identified associations between mutations in UGT8 and sporadic ALS, and between ST6GAL1 mutations and
conversion of mild cognitive impairment into clinical Alzheimer’s disease. In this review we consider potential mechanisms
connecting glycosyltransferase dysfunction to neurodegeneration. The most prominent candidates are ganglioside synthesis and
impaired addition of O-linked b-N-acetylglucosamine (O-GlcNAc) groups to proteins important for axonal and synaptic function.
Special consideration is given to examples where genetic mutations within glycosyltransferases are associated with neurodegenera-
tion in recognition of the fact that these changes are likely to be upstream causes present from birth.
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Introduction
Glycosyltransferases represent a large family of enzymes
that catalyse biosynthesis of oligosaccharides, polysacchar-
ides, and glycoconjugates. Sugar moieties are transferred
from activated sugar donors to specific acceptor molecules
via the formation of glycosidic bonds (Chuh et al., 2016).
Acceptor molecules include other sugars, nucleic acids,
lipids, and proteins. Glycosyltransferases reside predomin-
antly within the Golgi apparatus of eukaryotes as type II
transmembrane proteins. Over 90 glycosyltransferase
families have been described (www.cazy.org/GlycosylTran
sferases.html). Sequence alignment tools have been useful
for predicting glycosyltransferase function, including a
metal-binding motif important for configuration of sub-
strate within the active site (Lairson et al., 2008).
However, even closely related sequences have been shown
to exhibit different catalytic activity (Breton et al., 2006).
Glycosyltransferases are classified as either ‘retaining’ or
‘inverting’ enzymes according to whether the anomeric
bond within the donor substrate is retained or inverted
during the sugar transfer.
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Neurodegenerative diseases are increasing in frequency,
in part due to an ageing population. Despite this, neurode-
generative diseases represent a significant unmet health
need without effective treatments or clearly delineated
pathogenic mechanisms. Changes in expression levels of
glycosyltransferases have been strongly linked with neuro-
degeneration (Ludemann et al., 2005; Desplats et al., 2007;
Schneider 2018), but determining whether these effects are
upstream of neurotoxicity is difficult. Two distinct
glycosyltransferase-associated mechanisms are prominent:
ganglioside synthesis and addition of O-linked b-N-acetyl-
glucosamine to proteins (O-GlcNAcylation). Major gan-
gliosides are sialic acid-containing glycosphingolipids.
Within the mammalian brain they are synthesized in the
endoplasmic reticulum from a lactosylceramide precursor
before remodelling during transit from the cis- to the
trans-Golgi network by a series of glycosyltransferase en-
zymes (Fig. 1). Mature gangliosides are expressed on the
plasma membrane of most vertebrate cells and within
bodily fluids. They are particularly abundant on neuronal
and glial cells within the CNS where they are thought to
function prominently in cell signalling (Vajn et al., 2013).
Altered levels of gangliosides have been reported in animal
models of amyotrophic lateral sclerosis (ALS) and in post-
mortem CNS tissue from ALS patients (Ariga, 2014; Dodge
et al., 2015); similar findings have been reported in
Parkinson’s disease (Wu et al., 2012) and Alzheimer’s
disease (Gylys et al., 2007). O-GlcNAcylation occurs
predominantly in the brain and is regulated by
the glycosyltransferases O-linked N-acetylglucosamine
transferase (OGT) and EGF domain-specific O-linked
N-acetylglucosamine transferase (EOGT), which attach
the O-GlcNAc moiety to acceptor proteins at specific
serine/threonine residues via an O-linked glycosidic bond.
OGT acts intracellularly whereas EOGT acts extracellularly
on secreted and membrane proteins (Fig. 2).
O-GlcNAcylation of CNS proteins important for axonal
and synaptic function is significantly reduced in animal
models of neurodegenerative diseases and in patient tissue
from diseases including Parkinson’s disease, Huntington’s
Figure 1 Schematic overview of the biosynthesis and function of major gangliosides within the mammalian brain.
Lactosylceramide is synthesized at the cytoplasmic leaflet of the endoplasmic reticulum membrane from its ceramide precursor. De novo ceramide
is transported to the Golgi apparatus and is converted to glycosphingolipids and sphingomyelin through the addition of saccharides and
phosphocholine, respectively. Glycosphingolipids are transported in vesicles to the outer leaflet of the plasma membrane. Sialic acid-enriched
glycosphingolipids form gangliosides which are anchored to the membrane via their ceramide-lipid moiety. Four major gangliosides comprise
490% of total gangliosides within the brain. A-series gangliosides (red) are derived from GM3. B-series gangliosides (purple) are synthesized from
GM3 by GD3 synthase (St8sia1). G = the ‘ganglioside’ core; the second letter designates the quantity of sialic acid residues; M = mono; D = di; T
= tri. Gangliosides are essential to maintaining neuronal integrity with functions including, but not limited to, increasing the neuroprotective
properties of astrocytes, stabilizing interactions between neurons and glia, enhancing neurite outgrowth and negatively regulating neuroinflam-
mation through activation of the complement pathway.
Glycosyltransferases in neurodegeneration BRAIN 2020: 143; 1332–1340 | 1333
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disease, Alzheimer’s disease and ALS (Liu et al., 2004;
Ludemann et al., 2005; Kumar et al., 2014; Frenkel-
Pinter et al., 2017).
Neurodegenerative diseases exhibit late age of onset and
it is therefore assumed that genetic mutations are upstream
of disease pathogenesis. As a result, the discovery of neu-
rodegenerative disease-associated DNA mutations is a sig-
nificant step towards identification of upstream therapeutic
targets. We have recently discovered that mutations prox-
imal to the substrate-binding site of glycosyltransferase 8
domain-containing 1 (GLT8D1) disrupt enzyme activity
and are associated with familial ALS (Cooper-Knock et
al., 2019). Our work is the first evidence that dysfunction
of a glycosyltransferase is sufficient to cause a neurodegen-
erative disease. Our data are consistent with an effect of
GLT8D1 mutations on ganglioside synthesis. In support of
this mechanism, we have demonstrated by immunocyto-
chemistry that ALS-associated GLT8D1 mutations reduce
membrane expression of glycosphingolipids, which include
gangliosides, in human cells (unpublished data). Moreover,
in this review we summarize previous literature linking gen-
etic changes within glycosyltransferases to neurodegenera-
tion, and provide new evidence that genetic mutations
within EOGT are significantly associated with sporadic
ALS making this another upstream therapeutic target.
Impaired ganglioside
synthesis is linked to
neurodegeration
Parkinson’s disease
Reduced glycosyltransferase expression and lowered ganglio-
side synthesis has been implicated in the pathogenesis of
Parkinson’s disease. A recent report described a reduction
in gene expression of the glycosyltransferases B3GALT4
and ST3GAL2 in neuromelanin-containing neurons in the
substantia nigra of patients with Parkinson’s disease com-
pared to control subjects (Schneider, 2018). These genes
are key players in the ganglioside biosynthesis pathway
(Fig. 1). It is proposed that reduced B3GALT4 and
ST3GAL2 expression leads to vulnerability of dopaminergic
neurons via aberrant ganglioside synthesis. Consistent with
this hypothesis, the number of GM1 ganglioside-expressing
cells in the Parkinson’s disease substantia nigra are reduced
(Wu et al., 2012), and levels of the major brain ganglio-
sides—GM1, GD1a, GD1b and GT1b—are decreased in
whole substantia nigra homogenates from patients with
Parkinson’s disease (Seyfried et al., 2018). Model systems
provide evidence that dysfunction of ganglioside synthesis
is a cause and not just an association of typical
Parkinson’s disease pathology: genetically engineered mice
lacking major brain gangliosides display overt motor impair-
ment with increasing age, which is accompanied by loss of
dopaminergic neurons from the substantia nigra pars com-
pacta and aggregation of -synuclein (Wu et al., 2012).
Huntington’s disease
In a similar manner to Parkinson’s disease, reduced expres-
sion of glycosyltransferases involved in ganglioside synthe-
sis has also been described in the R6/1 mouse model of
Huntington’s disease and in human Huntington’s disease
patients (Desplats et al., 2007). In this study 480% of
gene expression changes observed in the striatum of R6/1
mice were also observed in the post-mortem caudate of
human Huntington’s disease subjects. Overlapping genes
were significantly enriched with glycosyltransferases
involved in ganglioside synthesis including ST3GAL5,
ST8SIA3, B4GALNT1 and ST3GAL2 (Fig. 1). Consistent
with impaired ganglioside synthesis, the same study
Figure 2 O-GlcNAcylation is implicated the pathophysi-
ology of neurodegenerative disease. An overview of
O-GlcNAcylation, a post-translational modification of O-GlcNAc,
which has been implicated in neurodegenerative diseases
Huntington’s disease, Alzheimer’s disease, Parkinson’s disease and
ALS. O-GlcNAcylation occurs predominantly in the brain and is
regulated by the glycosyltransferases OGT and EOGT, which attach
the O-GlcNAc moiety to acceptor proteins at specific serine/
threonine residues via an O-linked glycosidic bond; OGT acts
intracellularly whereas EOGT acts extracellularly on secreted and
membrane proteins.
1334 | BRAIN 2020: 143; 1332–1340 T. Moll et al.
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reported reduced ganglioside concentrations within both
the diseased human caudate and the mouse striatum. It
should be noted that despite significant homology to
ST8SIA1, which has a well described role in ganglioside
biosynthesis (Fig. 1), ST8SIA3 is traditionally associated
with N-glycosylation of secreted/membrane proteins
within the CNS (Lin et al., 2019). Like gangliosides, N-
glycosylated proteins are important for cell signalling.
Alzheimer’s disease
There is good evidence for perturbed ganglioside metabol-
ism in patients with Alzheimer’s disease, and in the devel-
opment of amyloid-b pathology in particular (Barrier et al.,
2007). In contrast to the findings in Parkinson’s disease and
Huntington’s disease, the key observation appears to be
increased ganglioside synthesis. Elevated GM1, GM2 and
GM3 levels have been reported in the cerebral cortices of
Alzheimer’s disease patients (Kracun et al., 1992; Gylys
et al., 2007). Development of amyloid-b deposition is the
defining pathology of Alzheimer’s disease and within brains
exhibiting early Alzheimer’s disease pathology, a significant
proportion of amyloid-b is bound to ganglioside species
(Yanagisawa and Ihara, 1998). It has even been suggested
that insoluble GM1-bound amyloid-b is the key toxin lead-
ing to neuronal death (Hayashi et al., 2004), as a result of
high affinity binding between GM1 and amyloid-b, which
facilitates formation of insoluble b-pleated sheets
(Yamamoto et al., 2007). With increasing age GM1 is loca-
lized to presynaptic nerve terminals and this may have a
role in directing amyloid-b deposition to the same locations
(Yamamoto et al., 2008). Unlike evidence regarding gan-
gliosides, reports of altered glycosyltransferase expression
in Alzheimer’s disease are more limited. There is evidence
that glycosyltransferase activity may modify Alzheimer’s
disease pathology: overexpression of the glycosyltransferase
B4GALNT1 leads to increased ganglioside expression but
also increases APP cleavage to form amyloid-b pathology
through suppression of lysosomal degradation of BACE1
(Yamaguchi et al., 2016). Currently, transgenic mouse
models of Alzheimer’s disease do not mirror changes in
ganglioside distribution seen in human post-mortem tissue
(Barrier et al., 2007).
Amyotrophic lateral sclerosis
ALS has been linked to abnormal lipid metabolism
(Desport et al., 2005) and in particular, gangliosides and
their ceramide precursors are thought to be modulators of
disease progression (Salazargrueso et al., 1990; Stevens
et al., 1993). Whether ganglioside production is increased
or decreased is controversial. As early as 1985 a 10% re-
duction in b-series gangliosides was identified within the
motor cortex of ALS brains compared to non-ALS controls
(Rapport et al., 1985). More recently elevated levels of
gangliosides GM1 and GM3 were reported within ALS
post-mortem spinal cords compared to age-matched
controls; findings were corroborated in the SOD1-G93A
transgenic ALS mouse model (Dodge et al., 2015).
Interestingly, autoantibodies against specific gangliosides
produce an inflammatory disease of spinal motor neurons
known as multifocal motor neuropathy with conduction
block (Harschnitz et al., 2014), which is a frequent differ-
ential diagnosis of ALS.
ALS specifically inflicts pathology on the upper and lower
motor neurons, the neuromuscular junction and muscle.
The accessibility of this system in disease models facilitates
the differentiation of up- and downstream disease associ-
ations. For example, increased expression of glycosphingo-
lipids is observed in muscle tissue from end-stage mutant
SOD1-ALS mice compared to controls, but similar changes
were observed in response to surgically-induced muscle de-
nervation suggesting a downstream effect (Henriques et al.,
2015). Moreover, neurotransmission at the neuromuscular
junction is unchanged in aged GM2 and GD3-deficient
mice compared to controls (Zitman et al., 2011).
However, our discovery that mutations in the glycosyl-
transferase GLT8D1 are a cause of familial ALS is a step
forward, which places glycosyltransferase activity irrefut-
ably upstream in the development of disease.
Genetic mutations in glyco-
syltransferases cause
neurodegeneration
Genetic mutations in the development of an age-associated
neurodegenerative disease are, by definition, upstream
causes or risk factors rather than secondary to the disease
process. Mutations discovered to date are included in
Table 1 and described below.
GLT8D1
A recent study from our lab demonstrated that mutations
within the glycosyltransferase domain of GLT8D1 are
associated with familial ALS (Cooper-Knock et al., 2019).
The function of GLT8D1 is unknown, but it is ubiquitously
expressed and localized to the Golgi apparatus. Based on
sequence homology, GLT8D1 is a member of glycosyltrans-
ferase family 8 and is expected to catalyse the transfer of a
glycosyl group from a donor to an acceptor via a ‘retain-
ing’ mechanism. Mutated GLT8D1 carrying ALS-associated
amino acid changes is toxic to neuronal and non-neuronal
cell lines, and induces motor deficits in zebrafish embryos;
these observations are consistent with a role in motor
neuron degeneration. Interestingly, relative toxicity of
ALS-associated mutations in model systems mirrors the
clinical severity. Glycosyltransferase enzyme activity is
reduced in the mutated form of GLT8D1 commensurate
with an increase in substrate affinity, which is predicted
to impair cycling of substrate through the enzyme and
thus reduce overall velocity (Cooper-Knock et al., 2019).
Glycosyltransferases in neurodegeneration BRAIN 2020: 143; 1332–1340 | 1335
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Taken together, these data are consistent with loss-of-func-
tion toxicity. Our study is the first time inherited mutations
that diminish glycosyltransferase enzyme activity have
been associated with ALS. We have recently demonstrated
by immunocytochemistry that ALS-associated mutations
reduce membrane expression of glycosphingolipids in
human cells (unpublished data). Glycosphingolipids include
gangliosides and this would be consistent with disruption
of ganglioside signalling within the CNS. GLT8D1 was re-
cently identified as a risk gene for schizophrenia (Yang
et al., 2018), and while schizophrenia is not a neurodegen-
erative disorder, it is noteworthy that ALS and schizophre-
nia share common genetic risk (McLaughlin et al., 2017).
UDP glycosyltransferase 8 (UGT8)
Like GLT8D1, UGT8 is a member of glycosyltransferase
family 8. UGT8 functions in the biosynthesis of galactocer-
ebroside, a sphingolipid that forms the myelin membrane in
the central and peripheral nervous systems. Rare and po-
tentially pathogenic copy number variants have been iden-
tified in the promotor region of UGT8 following in an
unbiased genome-wide screen for de novo DNA mutations
in 12 trios including sporadic ALS patients and unaffected
parents (Pamphlett et al., 2011). Abnormal lipid biosynthe-
sis and metabolism is a pathological hallmark of ALS
(Dupuis et al., 2008; Dorst et al., 2011), therefore it is
possible that UGT8 plays a role in the hypolipidaemia
observed in ALS patients and the SOD1-G93A ALS
mouse model (Kim et al., 2011; Yang et al., 2013). Mice
lacking Ugt8a, the orthologue of UGT8, exhibit impaired
locomotor activity and disruption in nerve conduction fol-
lowed by degeneration of the myelin sheath (Bosio et al.,
1996; Coetzee et al., 1996), which is rescued following
transgenic expression of UGT8A (Zoller et al., 2005).
Interestingly the rescue occurred with expression of
UGT8A under a promoter exclusively expressed within
oligodendrocytes, which is consistent with other evidence
implicating these cells in ALS-associated neurodegeneration
(Morrison et al., 2013).
ST6 b-galactoside a-2,6-sialyltransfer-
ase 1 (ST6GAL1)
ST6GAL1 is an ‘inverting’ enzyme and a member of glyco-
syltransferase family 29. ST6GAL1 catalyses the transfer of
sialic acid onto galactose-containing substrates including cell-
surface signalling lipids and proteins (Garnham et al., 2019).
A genome-wide association study implicated polymorphisms
within ST6GAL1 in the conversion of mild cognitive impair-
ment into clinical Alzheimer’s disease (Lee et al., 2017).
Interestingly ST6GAL1 is cleaved and occurs in a soluble
form; this cleavage is mediated by BACE1 (Kitazume et
al., 2001), which is also involved in the cleavage of APP
to form amyloid-b. Indeed, overexpression of ST6GAL1 in-
creases APP secretion (Nakagawa et al., 2006) suggesting
that the activity of ST6GAL1 can directly modify the central
pathway in the development of Alzheimer’s pathology.
Glycosyltransferase
O-GlcNAcylation: a key reg-
ulator of neurodegeneration?
Protein glycosylation and more specifically the addition of O-
GlcNAc groups to CNS proteins important for axonal and
synaptic function, is significantly reduced in animal models of
neurodegenerative diseases and in patient tissue from diseases
Table 1 Defects affecting specific glycosyltransferase enzymes observed in neurodegenerative disease
Glycosyltransferase Functional consequence Neurodegenerative
disorder
Defect observed Reference
ST6GAL1 Disrupted cell surface signalling Alzheimer’s disease DNA mutations Lee et al., 2017
B3GALT4 Reduced ganglioside biosynthesis
(GD1b)
Parkinson’s disease Reduced gene expression Schneider, 2018
ST3GAL2 Reduced ganglioside biosynthesis
(GT1b)
Parkinson’s disease
Huntington’s disease
Reduced gene expression Schneider, 2018
Desplats et al., 2007
B4GALNT1 Reduced ganglioside biosynthesis Huntington’s disease Reduced gene expression Desplats et al., 2007
ST8SIA3 Implicated in ganglioside biosyn-
thesis but described role in
N-glycosylation
Huntington’s disease Reduced gene expression Desplats et al., 2007
ST3GAL5 Reduced ganglioside biosynthesis Huntington’s disease Reduced gene expression Desplats et al., 2007
GLT8D1 Reduced membrane expression
of glycosphingolipids
ALS DNA mutations Cooper-Knock et al.,
2019
UGT8 Disruption of myelin synthesis ALS DNA mutations Pamphlett et al., 2011
EOGT Disruption of O-GlcNAcylation ALS DNA mutations This article
OGT Impaired O-GlcNAcylation Alzheimer’s disease
ALS
Reduced concentration of
O-GlcNAcylated proteins
Liu et al., 2004
Ludemann et al., 2005
OGT Excessive O-GlcNAcylation Parkinson’s disease Increased concentration of
O-GlcNAcylated proteins
Wani et al., 2017
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including Huntington’s disease, Alzheimer’s disease and ALS
(Liu et al., 2004; Ludemann et al., 2005; Kumar et al., 2014;
Frenkel-Pinter et al., 2017) (Table 1). O-GlcNAcylation is
reported to negatively regulate tau phosphorylation (Liu et
al., 2004), which is key in the pathogenesis of a number of
neurodegenerative diseases, including Alzheimer’s disease. In
contrast, an increase in O-GlcNAcylation is observed in the
post-mortem temporal cortex of patients with Parkinson’s
disease and is postulated to contribute to neurodegeneration
through the inhibition of autophagy leading to an increase in
-synuclein accumulation (Wani et al., 2017). Neurofilaments
are critical components of the neuronal cytoskeleton that can
undergo O-GlcNAcylation (Yuan et al., 2012).
Neurofilament levels are significantly higher in the serum
and CSF of ALS patients compared to control subjects
(Benatar et al., 2018). This increase is thought to be a con-
sequence of axonal damage. However, there is evidence that
neurofilament damage may be upstream in the pathogenesis
of ALS including the observation that increased phosphoryl-
ation of neurofilaments is associated with neurotoxicity
(Julien, 1997). It is thought that phosphorylation and
O-GlcNAcylation are reciprocal, meaning that reduced
O-GlcNAcylation could precipitate harmful phosphorylation;
indeed this has been observed in a transgenic rat model of
SOD1-ALS (Ludemann et al., 2005).
O-GlcNAcylation occurs predominantly in the brain and
is regulated by the glycosyltransferases OGT and EOGT;
the reverse reaction is catalysed by O-GlcNAcase (OGA).
Together these reactions constitute a dynamic and revers-
ible process (Fig. 2). OGT is an inverting enzyme and a
member of glycosyltransferase family 41; OGT is highly
enriched in the brain, where it is 10 times more active
than in peripheral tissue (Okuyama and Marshall, 2003).
OGT is localized to the nucleus, soma, dendrites and
presynaptic terminals of neurons (Akimoto et al., 2003).
Removal of postsynaptic OGT from primary neurons in-
hibits both synapse formation and the development of den-
dritic spines (Lagerlof et al., 2017). This highlights the
importance of OGT in maintaining synaptic stability, and
notably loss of synaptic stability is a unifying feature of
neurodegenerative disease. EOGT is an inverting enzyme
and a member of glycosyltransferase family 61. Despite
distinct sites of action, OGT and EOGT are both regulated
via the hexosamine biosynthetic pathway (Ogawa et al.,
2015). EOGT activity is involved in Notch signalling,
which is important for neurodevelopment. Indeed, homo-
zygous loss-of-function mutations in EOGT produce
Adams-Oliver syndrome, a congenital developmental dis-
order associated with actin cytoskeleton defects.
ALS-associated genetic variants
within O-GlcNAcylation pathway
enzymes
While homozygous EOGT mutations affect neurodevelop-
ment, we hypothesized that heterozygous mutations within
EOGT might negatively impact on the maintenance of axon
integrity and increase risk of developing ALS. To test this
hypothesis we performed rare-variant burden testing
(Cirulli et al., 2015) within EOGT to check for a genetic
association with ALS. We used whole genome sequencing
data from 4493 sporadic ALS patients and 1924 control
subjects (van der Spek et al., 2019); we identified 32 mis-
sense rare (MAF 5 1%) variants within EOGT that were
exclusively or predominantly found in ALS cases (Table 2).
When considering all rare missense variants found in cases
and controls across all exons of EOGT, there was a signifi-
cant enrichment of such mutations in ALS patients (Firth
logistic regression, P = 0.007). Similar testing did not iden-
tify an enrichment of ALS-associated mutations within
OGT, indeed we only identified two rare missense muta-
tions within OGT in 4493 sporadic ALS patients. It should
be noted that OGT is encoded on the X chromosome and
therefore males are necessarily hemizygous, which may pre-
dispose to a neurodevelopmental phenotype rather than a
late age-of-onset disease: for example mutations within N-
terminal tetratricopeptide repeats of OGT are associated
with X-linked intellectual disability (Gundogdu et al.,
2018). There was no significant burden of ALS-associated
mutations within OGA (P = 0.91).
Conclusions
Overall there is substantial evidence for dysfunction of gly-
cosyltransferases in neurodegenerative diseases including
ALS, Alzheimer’s disease, Huntington’s disease and
Parkinson’s disease. There are diverse functions associated
with glycosyltransferase activity and for many of the en-
zymes the biological pathway associated with their activity
is not yet clear. However, in our analysis, dysfunction
associated with neurodegenerative disease can be seen to
converge on the ganglioside synthesis pathway and altered
O-GlcNAcylation. The exact nature of the defect appears
to be variable in different diseases; for example ganglioside
concentrations are reduced in Parkinson’s disease and
Huntington’s disease, increased in Alzheimer’s disease and
there is evidence for change in both directions in ALS.
Similarly, increased O-GlcNAcylation is associated with
the development of Parkinson’s disease pathology but
reduced O-GlcNAcylation is associated with the develop-
ment of tau pathology. We suggest that consensus will arise
via efforts to position glycosyltransferase dysfunction
within the cascade of pathogenesis leading to neuronal
death—it is not glycosyltransferase dysfunction per se that
is interesting, but rather upstream changes in glycosyltrans-
ferase function that initiate toxicity. With this in mind we
have highlighted genetic associations between mutations in
glycosyltransferases and neurodegenerative disease. Most
prominently we have recently discovered autosomal dom-
inant mutations in GLT8D1 to be a monogenic cause of
ALS. Disease-associated mutations have also been dis-
covered in UGT8 and ST6GAL1; and we have revealed a
Glycosyltransferases in neurodegeneration BRAIN 2020: 143; 1332–1340 | 1337
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new association between ALS and mutations in EOGT.
Glycosyltransferases are likely to be an important thera-
peutic target in the effort of develop disease-modifying
therapies for neurodegenerative disease.
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